Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07803458

Attention-based Binocular Training for Impaired Stereopsis (BRAVE)

This study evaluates a novel attention-based binocular visual search training paradigm designed to improve stereopsis (stereo vision) in individuals with impaired binocular vision. Disruptions in balanced binocular input, such as from strabismus or anisometropia, often lead to deficient stereo vision, causing daily visuomotor limitations. While traditional therapies focus on monocular acuity, they frequently fail to restore stereopsis, especially in adults. The investigators propose a unique dichoptic visual search training method that embeds binocular disparity inside an attention-demanding task, encouraging cooperative binocular integration. Participants aged 18-39 with impaired stereopsis will be randomly assigned in a 1:1 ratio to either the active training group (disparity-embeded task) or the active control group (identical task with zero disparity). Both groups complete 5 training sessions over 5-6 weeks. Assessments will occur at baseline, immediately post-training, and at a 12-week follow-up. The primary objective is to determine if the active training group shows significantly greater improvements in local stereoacuity compared to the control group.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Eye and Vision Research Limited, Hong Kong, Hong Kong SAR

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-39 years (inclusive).
  • Deficient or anomalous stereoscopic vision with a stereoacuity >= 70 sec arc or unmeasurable stereoacuity.
  • Best corrected visual acuity (BCVA) of < 0.80 logMAR in both eyes, with at least one eye having a visual acuity of <= 0.1 logMAR (uncorrected or corrected-to-normal with glasses or contact lenses).
  • Normal colour vision.
  • Good general health.

Exclusion criteria

  • Previous history of ocular surgery (except for refractive correction surgery, where appropriate).
  • Pre-existing ocular conditions or medications that affect vision or visual function.
  • Pre-existing conditions or medications that affect neuropsychological function.
  • Presence of strabismus over 10 prism diopters at distance in current refractive correction measured by simultaneous prism and cover test, or large eccentric fixation.
  • Previous history of experiencing double vision (diplopia).
  • Identified at risk of developing diplopia due to binocular state and/or poor binocular control.
  • Inability to comprehend psychophysical test instructions given and/or consent for themselves.

Treatment and study plan

Attention-Guided Dichoptic Visual Search Training

Behavioral

A computer-based dichoptic training paradigm in which visual stimuli are presented separately to each eye under balanced interocular contrast . Participants search for conjunction-defined targets across 5 sessions (5 blocks of 192 trials per session). The target stimulus is uniquely paired with crossed binocular disparity to provide depth-based attentional guidance, with target disparity adaptively reduced based on search performance.

Zero-Disparity Dichoptic Visual Search Task

Behavioral

An active control dichoptic task identical in visual stimuli, trial structure (5 sessions; 5 blocks of 192 trials per session), and interocular contrast balancing to the training arm, but presented with zero binocular disparity (all stimuli appear in the same depth plane without depth cues).

Primary outcomes

  1. Change in Local Stereoacuity

    Time frame: Baseline (T0) and Immediately Post-Training (T1, within 7 days after Session 5, approximately 5-6 weeks from baseline).

    Measured using the Randot Stereotest - Circles test (graded disparities from 400 to 20 arcsec, 10 levels) under standardized lighting at 40 cm. The score is recorded as the finest disparity correctly identified (in log arcseconds). Nil stereopsis is assigned 3000 arcsec (3.477 log arcsec). The primary metric is the between-group difference in the change score.

Secondary outcomes

  1. Retention of Local Stereoacuity Gains

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Measured using the Randot Stereotest - Circles test under crossed disparity (log10 arcsec; nil stereopsis assigned 3000 arcsec) to evaluate long-term maintenance of training effects

  2. Change in Uncrossed Local Stereoacuity

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Measured using the Randot Stereotest - Circles test with the test booklet rotated 180 degrees (log10 arcsec; nil stereopsis assigned 3000 arcsec).

  3. Change in Global Stereoacuity

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Measured with the Randot Preschool Stereotest (random-dot stereograms, 800 to 40 arcsec, 6 levels) under both crossed and uncrossed disparity conditions (log10 arcsec; nil stereopsis assigned 3000 arcsec).

  4. Change in Laboratory-Based Stereoacuity Threshold

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Psychophysical stereoacuity threshold (75% threshold in log10 arcsec) measured using a 4-alternative forced-choice staircase ring test administered dichoptically.

  5. Change in Best-Corrected Visual Acuity (BCVA)

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Monocular (affected/dominant eyes) and binocular distance visual acuity measured using an electronic ETDRS logMAR chart at 4 meters (recorded in logMAR units).

  6. Change in Interocular Suppression Status

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Binocular status classified into categorical states (fusion, suppression, or diplopia) using the Worth 4-dot test at near (40 cm) and distance (3 m).

  7. Change in Interocular Suppression Strength (Contrast Balance Ratio)

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Effective suppression depth quantified by the interocular contrast ratio at the perceptual balance point measured via a dichoptic letter-polarity task.

  8. Change in Visual Evoked Potentials (VEPs)

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Peak latencies (ms) and amplitudes (μV) of the transient pattern-reversal VEP N75-P100-N135 complex across high-contrast and isoluminant red-green conditions, alongside harmonic amplitudes/phases (2F, 4F) from steady-state VEPs, recorded via a 64-channel EEG system.

  9. Change in Electrophysiological Marker of Attentional Selection (N2pc Component)

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Mean amplitude (μV) of the posterior contralateral-minus-ipsilateral difference wave (N2pc) extracted across predefined parieto-occipital electrodes (P7, PO7, P8, PO8) during a modified spatial cueing task.

  10. Change in Behavioral Selective Attention

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Spatial cueing effects on mean reaction time (ms) and response accuracy (%) derived from the modified spatial cueing task.

  11. Change in Visual Search Efficiency

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Visual search slope (reaction time as a function of set size, in ms/item) measured from a 192-trial zero-disparity dichoptic visual search task.

  12. Change in Visuomotor Coordination Completion Time and Kinematic Parameters

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Visuomotor dexterity and kinematic performance are assessed using the Grooved Pegboard Test separately for dominant and non-dominant hands. Hand movements during the task are video recorded for detailed kinematic tracking. The primary quantitative metric for this outcome is the total completion time (in seconds) required to successfully place all 25 grooved pegs (shorter duration indicates better motor speed and coordination). Secondary kinematic metrics extracted from video analyses include mean peg-insertion duration (seconds), inter-peg temporal variability across the 25 trials (coefficient of variation, CV), and total drop/error counts.

  13. Change in Quality of Life Scores

    Time frame: Baseline (T0), Immediately Post-Training (T1), and 12-Week Follow-Up (T2).

    Domain scores assessed via the World Health Organization Quality of Life Instrument-Short Form (WHO QoL-BREF) and the Amblyopia and Strabismus Questionnaire (A&SQ). Higher scores indicate superior functional visual ability and quality of life. For both questionnaires, domain and composite scores are linearly transformed to a standardized 0 to 100 scale, where higher scores represent superior functional visual ability, fewer daily limitations, and better overall quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Benjamin Thompson, PhD

CONTACT

[email protected]

+852-31699631

Jeffrey TW Leung, PhD

CONTACT

[email protected]

+852-64080394

Sponsors and collaborators

Lead sponsor

Centre for Eye and Vision Research

Other

Collaborators

  • The Hong Kong Polytechnic University
  • University of Waterloo

Registry information

Official study title

Binocular Recovery Through Attention-based Visual Enhancement: A Randomized Controlled Trial (BRAVE Trial)

Acronym: BRAVE

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Sep 3, 2026
Registry last updated
Sep 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.